Document:

Exhibit 10.3(E)

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

CONFIDENTIAL

 

January 9, 2014

 

Marina Biotech, Inc.

3830 Monte Villa Parkway

Bothell, Washington, 98021

Attn: Michael French, Chief executive Officer

 

Re:                             Agreement re Option Compound and miR-34 Sequences

 

Dear Michael:

 

As you know, Mirna Therapeutics, Inc. (“MirnaRx”) and Marina Biotech, Inc. (“Marina Bio”) have entered into an amendment, effective as December 27, 2013, to that certain license agreement dated December 22, 2011 (the “License Agreement”, and such amendment the “Amendment”).  This letter agreement is that certain Amendment Side Letter referred to in the Amendment, and it sets forth the RNA oligonucleotide sequences of the Option Compounds that the Parties are agreeing to designate as Selected MirnaRx Compounds pursuant to the terms of the License Agreement.  Capitalized terms not defined in this Amendment Side Letter shall have the meaning given to those terms in the License Agreement.

 

The Parties hereby agree that the list of RNA oligonucleotide sequences attached as the Appendix of this Amendment Side Letter comprises sequences of miR-34, let-7, miR-25, [***] as well as the sequences of two Option Compounds [***] under the terms of the License Agreement.  The Parties further agree that such sequences are the highly confidential information of MirnaRx, and Marina Bio shall comply with the confidentiality obligations set forth in the License Agreement with respect thereto, and shall not disclose such sequences to any third party or use them for any purpose outside of the License Agreement.

 

	
AGREED TO BY:
    	
Mirna   Therapeutics, Inc.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Signature:
    	
/s/   Paul Lammers
    
	
 
    	
 
    	
Paul   Lammers, M,D., M.Sc.
    
	
 
    	
 
    	
Chief   Executive Officer
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Marina   Biotech, Inc.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Signature:
    	
/s/   Michael French
    
	
 
    	
 
    	
Michael   French
    
	
 
    	
 
    	
Chief   Executive Officer
    

 

 

CONFIDENTIAL

 

APPENDIX

 

miR-34 Sequence:

[***]

 

[***]

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.Exhibit 10.3(F)

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

AMENDMENT No. 2 to LICENSE AGREEMENT

 

This AMENDMENT NO. 2 to LICENSE AGREEMENT (this “Amendment No. 2”) is made and entered into effective as of May 11, 2015 (the “Amendment No. 2 Effective Date”), by and between Mirna Therapeutics, Inc., a Delaware corporation with offices at 2150 Woodward Street, Suite 100, Austin, Texas 78744 (“MirnaRx”), and Marina Biotech, Inc., a Delaware corporation with offices c/o Pryor Cashman LLP, 7 Times Square, New York, New York 10036 (“Marina Bio”).

 

WHEREAS, MirnaRx and Marina Bio are parties to a License Agreement dated December 22, 2011, as amended by the Letter Amendment dated November 16, 2012, and Amendment No. 1, dated December 27, 2013 (“Amendment No. 1”) and as further supplemented by that certain Amendment Side Letter referred to in Amendment No. 1, dated January 9, 2014 (collectively, the “License Agreement”);

 

WHEREAS, pursuant to the License Agreement, Marina Bio granted to MirnaRx a license under Marina’ Bio’s technology and intellectual property rights relating to Marina Bio’s liposomal delivery technology known as NOV340 (the “Marina Technology”), to develop and commercialize drug products incorporating such Marina Technology in combination with MirnaRx’s proprietary compound miR-34, and other specified compounds selected by MirnaRX pursuant to the terms of the License Agreement; and

 

WHEREAS, MirnaRx and Marina Bio desire to amend the License Agreement to modify the consideration payable by MirnaRx to Marina Bio with respect to development of products containing miR-34 and using the Marina Technology.

 

NOW THEREFORE, in consideration of the foregoing premises, the mutual promises and covenants of the Parties hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows.

 

1.1.                            Amendment of License Agreement. In accordance with Section 12.1 of the License Agreement, the Parties hereby agree to amend the License Agreement, effective as of the Amendment No. 2 Effective Date, in accordance with the remainder of this Section 1.  Capitalized terms not defined in this Amendment No. 2 shall have the meaning given to those terms in the License Agreement.  With the exception of those sections of the License Agreement that are expressly amended by this Amendment No. 2, the remainder of the License Agreement as in effect prior to the date hereof shall remain in full force and effect as provided therein.

 

1.2.                            Section 5.3(c) (as amended by Amendment No. 1) shall be amended and restated in its entirety with the following:

 

5.3(c)  Notwithstanding Sections 5.3(a) and 5.3(b) and the milestone table above, and solely with respect to Licensed Products containing or incorporating miR-34:

 

 

(i) no Milestone Payment shall be payable by MirnaRx for (A) achievement of the Milestone Event [***] of the milestone table above, or (B) any [***] of the milestone table above; and

 

(ii) with respect to the Milestone Payment payable to Marina Bio [***] of the milestone table above, MirnaRx may elect to pre-pay such Milestone Payment to Marina Bio prior to the achievement of such Milestone Event (the “miR-34 Prepayment”), and if such miR-34 Prepayment is made to Marina Bio on or before May 13, 2015 (the “Prepayment Date”), such Milestone Payment shall be [***].  Marina Bio agrees that if the miR-34 Prepayment is made on or before the Prepayment Date, such payment shall constitute [***] of the milestone table.

 

For clarity, Sections 5.3(a) and 5.3(b) and the milestone table shall apply in full to all Licensed Products other than any Licensed Product containing or incorporating miR-34, unless the Parties mutually agree otherwise in writing.

 

1.3.                            No Other Amendments.  Except as specifically modified herein, the remaining terms of the License Agreement shall remain in full force and effect.

 

1.4.                            Prepayment.  MirnaRx hereby agrees to pay to Marina Bio, within five (5) business days after the Amendment No. 2 Effective Date, an amount equal to [***] of the License Agreement for a Licensed Product containing the Selected MirnaRx Compound miR-34, in accordance with Section 5.3(c) of the License Agreement, as amended by this Amendment No. 2.

 

1.5.                            Counterparts; Facsimile Execution.  This Amendment No. 2 may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  This Amendment No. 2 may be executed by facsimile signatures and such signatures shall be deemed to bind each Party as if they were original signatures.

 

[Signature Page Follows]

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

IN WITNESS WHEREOF, the Parties have caused this Amendment No. 2 to be executed by their respective officers thereunto duly authorized as of the Amendment Effective Date.

 

 

	
MIRNA THERAPEUTICS, INC.
    	
 
    	
MARINA   BIOTECH, INC.
    
	
 
    	
 
    	
 
    
	
Signature   :
    	
/s/   Dr. Paul Lammers
    	
 
    	
Signature   :
    	
/s/   J. Michael French
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name   :
    	
Dr. Paul   Lammers
    	
 
    	
Name   :
    	
J.   Michael French
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title   :
    	
President &   CEO
    	
 
    	
Title   :
    	
President &   CEO
    

 

[Signature page to Amendment No. 2 to License Agreement]Exhibit 10.3(G)

 

[MIRNA THERAPEUTICS LETTERHEAD]

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

CONFIDENTIAL

 

August 24, 2015

 

Marina Biotech, Inc.

3830 Monte Villa Parkway

Bothell, Washington 98201

Attn: J. Michael French, President & Chief Executive Officer

 

Re: Selection and Agreement Regarding Option Compound

 

Dear Michael:

 

Reference is made to that certain License Agreement effective December 22, 2011 by and between Mirna Therapeutics, Inc., a Delaware corporation (“MirnaRx”), and Marina Biotech, Inc., a Delaware corporation (“Marina Bio”), as amended by Amendment No. 1 effective December 27, 2013 and Amendment No. 2 effective May 11, 2015, and as further supplemented by Side Letters dated December 22, 2011, November 16, 2012, and January 9, 2014 (collectively, as amended, the “Agreement”).  Capitalized words used but not defined herein shall have the meaning ascribed to such terms in the Agreement.

 

MirnaRx and Marina Bio agree as follows:

 

1.              MirnaRx desires to select the Option Compound [***] as the fifth Selected MirnaRx Compound in accordance with Section 2.6 of the Agreement.  Marina Bio confirms that the selected Option Compound is Available and shall be deemed a Selected MirnaRx Compound.

 

2.              With respect to the associated selection fee payment set forth in Section 5.2(b)(i) of the Agreement, (a) the initial portion of the selection fee shall be [***] provided that it is [***] by MirnaRx to Marina Bio on or before [***], and (b) the [***] due upon MirnaRx’s sublicensing to a Sublicensee of the Licensed Product containing the selected Selected MirnaRx Compound, as set forth in Section 5.2(b)(ii) of the Agreement.

 

3.              The sequence of the selected Selected MirnaRx Compound is the highly confidential information of MirnaRx, and Marina Bio shall comply with the confidentiality obligations set forth in the Agreement with respect thereto.

 

 

4.              This side letter (the “Side Letter”) shall be subject to the terms and conditions of the Agreement; provided that, to the extent that the terms set forth in this Side Letter conflict with the terms of the Agreement, the terms of this Side Letter shall govern and control.

 

 

	
AGREED   TO BY:
    	
MIRNA   THERAPEUTICS, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Signature:
    	
/s/   Casi DeYoung
    
	
 
    	
Casi   DeYoung
    
	
 
    	
Chief   Business Officer
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
MARINA   BIOTECH, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Signature:
    	
/s/   J. Michael French
    
	
 
    	
J.   Michael French
    
	
 
    	
President &   Chief Executive Officer
    

 

Mirna Therapeutics Inc. | 2150 Woodward St., Suite 100 | Austin, TX  78744 | 1.512.901.0900 | www.mirnarx.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]